Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;13(6):467-75.
doi: 10.1007/s11920-011-0232-0.

Is depression an inflammatory disorder?

Charles L Raison  1 , Andrew H Miller
Affiliations
Review

Is depression an inflammatory disorder?

Charles L Raison et al. Curr Psychiatry Rep. 2011 Dec.

Abstract

Studies consistently report that groups of individuals with major depressive disorder (MDD) demonstrate increased levels of a variety of peripheral inflammatory biomarkers when compared with groups of nondepressed individuals. These findings are often interpreted as meaning that MDD, even in medically healthy individuals, may be an inflammatory condition. In this article, we examine evidence for and against this idea by looking more closely into what the actual patterns of inflammatory findings indicate in terms of the relationship between MDD and the immune system. Data are presented in support of the idea that inflammation only contributes to depression in a subset of patients versus the possibility that the depressogenic effect of inflammatory activation is more widespread and varies depending on the degree of vulnerability any given individual evinces in interconnected physiologic systems known to be implicated in the etiology of MDD. Finally, the treatment implications of these various possibilities are discussed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Evidence supporting the importance of immune response amplifiers in the etiology of immune-based depression. Studies using exposure to a constant dosage of inflammatory input have identified multiple pathways by which immune activation produces depressive symptoms. This figure illustrates patterns of physiologic vulnerability in such pathways, using treatment with interferon (IFN)-α as a model system for chronic cytokine exposure. Immune response amplifiers identified in response to an initial dose of IFN-α include increased activation of p38 mitogen-activated protein kinase (MAPK), an important intracellular proinflammatory signaling cascade, and increased response of corticotropin-releasing hormone (CRH) pathways. Although not a physiologic pathway per se, increased sickness-type symptoms in response to a first dose of IFN-α predict the later development of full major depressive disorder. In terms of patterns of functional disability in response to chronic cytokine exposure, evidence suggests that individuals with any of the following changes are at significantly increased risk of developing significant depressive symptoms during IFN-α treatment: 1) increased peripheral proinflammatory cytokine concentrations (eg, tumor necrosis factor-α or interleukin-6), 2) flattening of the diurnal cortisol rhythm and increased evening cortisol, 3) increased peripheral and central nervous system concentrations of kynurenine and its metabolite quinolinic acid, and 4) disrupted sleep as reflected by reduced slow-wave sleep and diminished sleep efficiency. Importantly, all these changes have been observed in the context of idiopathic major depressive disorder in medically healthy individuals. BDNF—brain-derived neurotrophic factor; CSF—cerebrospinal fluid; HPA—hypothalamic-pituitary-adrenal (axis)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun. 2011;25:221–9. - PMC - PubMed
    1. O'Connor MF, Bower JE, Cho HJ, et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009;23:887–97. - PMC - PubMed
    1. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol. 2010;23:417–22. - PubMed
    1. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–41. - PMC - PubMed
    1. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57. - PubMed

Publication types

MeSH terms

LinkOut - more resources